<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446224</url>
  </required_header>
  <id_info>
    <org_study_id>114428</org_study_id>
    <secondary_id>WEUKSTV4602</secondary_id>
    <nct_id>NCT01446224</nct_id>
  </id_info>
  <brief_title>Cardiovascular and Torsades de Pointes Monitoring for Pazopanib</brief_title>
  <official_title>Postmarketing Cardiovascular Ischemia and Torsades de Pointes Monitoring for Pazopanib Using Observational Databases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study is conducted as part of a systematic pharmacovigilance activity, to
      provide a population-based context for Pazopanib use outside of the clinical trial setting.
      The aims of the study are to examine the incidence of cardiovascular ischemia (including
      myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular
      accident) and cardiac arrhythmia (Torsades de Pointes) in renal cell carcinoma patients
      treated with marketed anti-VEGF agents [Pazopanib (VOTRIENT), Bevacizumab (AVASTIN),
      Sorafenib (NEXAVAR), and Sunitinib (SUTENT)].

      Two databases will be utilized for this study: a large healthcare claims database in the U.S.
      and the Dutch linked medical registries (PHARMO RLS). The databases will provide large,
      geographically varied, non-trial populations in which to examine the incidence of the stated
      cardiovascular ischemic events and Torsades des Pointes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular ischemia</measure>
    <time_frame>Over four years from approval of pazopanib</time_frame>
    <description>Cardiovascular ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Torsades de Pointes</measure>
    <time_frame>Over four years from approval of pazopanib</time_frame>
    <description>Torsades de Pointes</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Subjects who experience cardiac ischemia</arm_group_label>
    <description>Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who do not experience cardiac ischemia</arm_group_label>
    <description>Subjects who do not experience cardiac ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who experience Torsades de Pointes</arm_group_label>
    <description>Subjects who experience Torsades de Pointes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who do not experience Torsades de Pointes</arm_group_label>
    <description>Subjects who do not experience Torsades de Pointes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Patients treated with pazopanib</description>
    <arm_group_label>Subjects who experience cardiac ischemia</arm_group_label>
    <arm_group_label>Subjects who experience Torsades de Pointes</arm_group_label>
    <arm_group_label>Subjects who do not experience cardiac ischemia</arm_group_label>
    <arm_group_label>Subjects who do not experience Torsades de Pointes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other anti-VEGFs</intervention_name>
    <description>Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib</description>
    <arm_group_label>Subjects who experience cardiac ischemia</arm_group_label>
    <arm_group_label>Subjects who experience Torsades de Pointes</arm_group_label>
    <arm_group_label>Subjects who do not experience cardiac ischemia</arm_group_label>
    <arm_group_label>Subjects who do not experience Torsades de Pointes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study cohorts will be created in two healthcare databases to follow the outcomes of
        interest in (i) Pazopanib users, and (ii) users of other marketed anti-VEGF drugs
        (Bevacizumab, Sorafenib, Sunitinib).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The anti-VEGF cohorts will include patients with the following characteristics:

          -  Adult patients (age â‰¥18 years)

          -  Prescribed or administered an anti-VEGF agent: Pazopanib, Bevacizumab, Sorafenib or
             Sunitinib on or after approval date of Pazopanib

          -  Diagnosed with renal cell cancer

        Exclusion Criteria:

          -  Patients with multiple primary cancer diagnoses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adverse events</keyword>
  <keyword>pazopanib</keyword>
  <keyword>Torsades des Pointes</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>anti-VEGF agents</keyword>
  <keyword>observational data</keyword>
  <keyword>cardiac ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Torsades de Pointes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

